Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies

MLA

Boris Campillo-Gimenez, et al. “Prognostic Impact of Thyroid Dysfunctions on Progression-Free Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Antibodies.” Melanoma Research, vol. 31, June 2021, pp. 208–17. EBSCOhost, https://doi.org/10.1097/cmr.0000000000000739.

APA

Boris Campillo-Gimenez, Eva Jali, Alexandra Frelau, Monica Dinulescu, Lise Boussemart, Marc Pracht, Marc Porneuf, Julien Edeline, & Thierry Lesimple. (2021). Prognostic impact of thyroid dysfunctions on progression-free survival in patients with metastatic melanoma treated with anti-PD-1 antibodies. Melanoma Research, 31, 208–217. https://doi.org/10.1097/cmr.0000000000000739

Chicago

Boris Campillo-Gimenez, Eva Jali, Alexandra Frelau, Monica Dinulescu, Lise Boussemart, Marc Pracht, Marc Porneuf, Julien Edeline, and Thierry Lesimple. 2021. “Prognostic Impact of Thyroid Dysfunctions on Progression-Free Survival in Patients with Metastatic Melanoma Treated with Anti-PD-1 Antibodies.” Melanoma Research 31 (June): 208–17. doi:10.1097/cmr.0000000000000739.